Sjögren’s syndrome is a common autoimmune rheumatic disease. The most common symptoms of Sjögren’s syndrome are extreme tiredness, along with dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). Saliva plays an essential role in numerous functions of the mouth. Xerostomia can be caused by medications, chronic diseases like Sjögren’s syndrome, and medical treatments, such as radiation therapy and bone marrow transplant. Xerostomia can eventually lead to difficulty in swallowing, severe and progressive tooth decay, or oral infections. Despite having excellent oral hygiene, individuals with Sjögren’s syndrome have elevated levels of dental caries, along with the loss of many teeth, early in the disease. Sjögren’s syndrome alters the protein profile and brings about a change in the composition of saliva. There is an increase in the levels of lactoferrin, β2-microglobulin, sodium, lysozyme C, and cystatin C, and a decrease in salivary amylase and carbonic anhydrase. Up to 90% of individuals with Sjögren’s syndrome have antibodies targeting the Ro 60 and La autoantigens. Natural aging, regardless of Sjögren’s syndrome, is also another factor that brings about a significant change in the composition of saliva. The most prevailing cause of xerostomia in elderly persons is the use of anticholinergic medications. Currently, there is no cure for Sjögren’s syndrome, and treatment is mainly palliative.
Get full access to this article
View all access options for this article.
References
1.
Alexander EL, Malinow K, Lejewski JE, Jerden MS, Provost TT, Alexander GE -1986-. Primary Sjögren’s syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med104:323–330.
2.
Amarasena R, Bowman S -2007-. Sjögren’s syndrome. Clin Med7:53–56.
3.
Ambudkar IS -2000-. Regulation of calcium in salivary gland secretion -review-. Crit Rev Oral Biol Med11:4–25.
4.
Asselin-Paturel C, Trinchieri G -2005-. Production of type I interferons: plasmacytoid dendritic cells and beyond -review-. J Exp Med202:461–465.
5.
Astor FC, Hanft KL, Ciocon JO -1999-. Xerostomia: a prevalent condition in the elderly. Ear Nose Throat J78:476–479.
6.
Bacman S, Berra A, Sterin-Borda L, Borda E -2001-. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. Invest Ophthalmol Vis Sci42:321–327.
7.
Baum BJ, Fox PC, Neumann RD -1996-. The salivary glands. In: Nuclear medicine. Harbert JC, Eckelman WC, Neumann RC, editors. New York: Thieme, pp. 439–444.
8.
Bergdahl M, Bergdahl J -2000-. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res79:1652–1658.
9.
Beroukas D, Hiscock J, Jonsson R, Waterman SA, Gordon TP -2001-. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjögren’s syndrome. Lancet358:1875–1876.
10.
Beroukas D, Hiscock J, Gannon BJ, Jonsson R, Gordon TP, Waterman SA -2002-. Selective downregulation of aquaporin-1 in salivary glands in primary Sjögren’s syndrome. Lab Invest82:1547–1552.
11.
Berra A, Sterin-Borda L, Bacman S, Borda E -2002-. Role of salivary IgA in the pathogenesis of Sjögren syndrome. Clin Immunol104:49–57.
12.
Bertorello R, Cordone MP, Contini P, Rossi P, Indiveri F, Puppo F, et al. -2004-. Increased levels of interleukin-10 in saliva of Sjögren’s syndrome patients: correlation with disease activity. Clin Exp Med4:148–151.
13.
Bolstad AI, Jonsson R -1998-. The role of apoptosis in Sjögren’s syndrome. Ann Med Interne149:25–29.
14.
Bolstad AI, Jonsson R -2002-. Genetic aspects of Sjögren’s syndrome. Arthritis Res4:353–359.
15.
Bolstad AI, Haga HJ, Wassmuth R, Jonsson R -2000-. Monozygotic twins with primary Sjögren’s syndrome. J Rheumatol27:2264–2266.
16.
Bombardieri M, Barone F, Pittoni V, Alessandri C, Conigliaro P, Blades MC, et al. -2004-. Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren’s syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther6:447–456.
17.
Breiman L, Friedman JH, Olshen RA, Stone CJ -1985-. Classification and regression trees. Belmont, CA: Wadsworth.
Cavill D, Waterman SA, Gordon TP -2004-. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjögren’s syndrome. Scand J Immunol59:261–266.
20.
Christensen LB, Petersen PE, Thorn JJ, Schiødt M -2001-. Dental caries and dental health behavior of patients with primary Sjögren syndrome. Acta Odontol Scand59:116–120.
21.
Daniels TE, Fox PC -1992-. Salivary and oral components of Sjögren’s syndrome -review-. Rheum Dis Clin North Am18:571–589.
22.
Dawes C -1987-. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res66:648–653.
23.
Delaleu N, Jonsson R, Koller MM -2005-. Sjögren’s syndrome -review-. Eur J Oral Sci113:101–113.
24.
Eriksson P, Andersson C, Ekerfelt C, Emerudh J, Skogh T -2004-. Relationship between serum level of IL-18 and IgG1 in patients with primary Sjögren’s syndrome, rheumatoid arthritis and healthy controls. Clin Exp Immunol137:617–620.
25.
Farris AD, Gross JK, Hanas JS, Harley JB -1996-. Genes for murine Y1 and Y3 Ro RNAs have class 3 RNA polymerase III promoter structures and are unlinked on mouse chromosome 6. Gene174:35–42.
26.
Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. -2002-. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med162:1293–1300.
27.
Fox PC, Brennan M, Pillemer S, Radfar L, Yamano S, Baum BJ -1998-. Sjögren’s syndrome: a model for dental care in the 21st century -review-. J Am Dent Assoc129:719–728.
28.
Fox RI -2002-. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren’s syndrome -review-. Adv Exp Med Biol506-Pt B-:1107–1116.
29.
Fox RI, Törnwall J, Maruyama T, Stern M -1998-. Evolving concepts of diagnosis, pathogenesis, and therapy of Sjögren’s syndrome -review-. Curr Opin Rheumatol10:446–456.
Gibson J, Halliday JA, Ewert K, Robertson S -2007-. Verifiable CPD paper: a controlled release pilocarpine buccal insert in the treatment of Sjögren’s syndrome. Br Dent J202:E17.
32.
Goldenberg DM -2006-. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther6:1341–1353.
33.
Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. -2006-. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci USA103:2770–2775; erratum in Proc Natl Acad Sci USA 103:5242, 2006.
34.
Halse AK, Harley JB, Kroneld U, Jonsson R -1999-. Ro/SSA reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjögren’s disease. Clin Exp Immunol115:203–207.
35.
Hammi AR, Al-Hashimi IH, Nunn ME, Zipp M -2005-. Assessment of SS-A and SS-B in parotid saliva of patients with Sjögren’s syndrome. J Oral Pathol Med34:198–203.
36.
Hansen A, Lipsky PE, Dorner T -2005-. Immunopathogenesis of primary Sjögren’s syndrome: implications for disease management and therapy -review-. Curr Opin Rheumatol17:558–565.
37.
Harley JB, Scofield RH -1991-. Systemic lupus erythematosus: RNA protein autoantigens, models of disease heterogeneity, and theories of etiology. J Clin Immunol11:297–316.
38.
Hendrick JP, Wolin SL, Rinke J, Lerner MR, Steitz JA -1981-. Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. Mol Cell Biol1:1138–1149.
39.
Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL -1979-. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med301:5–8.
40.
Hsu S, Dickinson D -2006-. A new approach to managing oral manifestations of Sjögren’s syndrome and skin manifestations of lupus. J Biochem Mol Biol39:229–239.
41.
Hsu S, Dickinson D, Qin H, Borke J, Ogbureke K, Winger J, et al. -2007-. Green tea polyphenols reduce autoimmune symptoms in a murine model for human Sjögren’s syndrome and protect human salivary acinar cells from TNF-alpha-induced cytotoxicity. Autoimmunity40:138–147.
42.
Hsu TC, Chang CH, Lin MC, Liu ST, Yen TJ, Tsay GJ -2006-. Anti-CENP-H antibodies in patients with Sjögren’s syndrome. Rheumatol Int26:298–303.
43.
Hunziker L, Recher M, Macpherson AJ, Ciurea A, Freigang S, Hengartner H, et al. -2003-. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat Immunol4:343–349.
44.
Ishikawa Y, Skowronski MT, Ishida H -2000-. Persistent increase in the amount of aquaporin-5 in the apical plasma membrane of rat parotid acinar cells induced by a muscarinic agonist SNI-2011. FEBS Lett477:253–257.
45.
Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K -2006-. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum54:2300–2305.
46.
Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. -1978-. Increased risk of lymphoma in sicca syndrome. Ann Intern Med89:888–892.
47.
Khurshudian AV -2003-. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod95:38–44.
48.
Kurien BT, Asfa S, Li C, Dorri Y, Jonsson R, Scofield RH -2005-. Induction of oral tolerance in experimental Sjögren’s syndrome autoimmunity. Scand J Immunol61:418–425.
49.
Langegger C, Wenger M, Duftner C, Dejaco C, Baldissera I, Moncayo R, et al. -2007-. Use of the European preliminary criteria, the Breiman-classification tree and the American-European criteria for diagnosis of primary Sjögren’s syndrome in daily practice: a retrospective analysis. Rheumatol Int27:699–702.
50.
Li J, Ha YM, Ku NY, Choi SY, Lee SJ, Oh SB, et al. -2004-. Inhibitory effects of autoantibodies on the muscarinic receptors in Sjögren’s syndrome. Lab Invest84:1430–1438.
51.
Liljemark WF, Gibbons RJ -1972-. Proportional distribution and relative adherence of Streptococcus miteor -mitis- on various surfaces in the human oral cavity. Infect Immun6:852–859.
52.
Luyk NH, Doyle T, Ferguson MM -1991-. Recent trends in imaging the salivary glands -review-. Dentomaxillofac Radiol20:3–10.
53.
MacFarlane TW, Mason DK -1974-. Changes in the oral flora in Sjögren’s syndrome. J Clin Pathol27:416–419.
54.
Mackay F, Browning JL -2002-. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol2:465–475.
55.
Mackay F, Sierro F, Grey ST, Gordon TP -2005-. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun8:243–265.
56.
Mandel L -2006-. An unusual pattern of dental damage with salivary gland aplasia. J Am Dent Assoc137:984–989.
57.
Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. -2004-. Inefficacy of infliximab in primary Sjögren’s syndrome: results of the randomized, controlled trial of Remicade in primary Sjögren’s syndrome -TRIPSS-. Arthritis Rheum50:1270–1276.
58.
Marsh PD -1999-. Microbiologic aspects of dental plaque and dental caries -review-. Dent Clin North Am43:599–614.
59.
Marton K, Boros I, Varga G, Zelles T, Fejerdy P, Zeher M, et al. -2006-. Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjögren’s syndrome. Oral Dis12:480–486.
60.
Matsumoto N, Salam MA, Watanabe H, Amagasa T, Senpuku H -2004-. Role of gene E2f1 in susceptibility to bacterial adherence of oral streptococci to tooth surfaces in mice. Oral Microbiol Immunol19:270–276.
61.
Mavragani CP, Moutsopoulos NM, Moutsopoulos HM -2006-. The management of Sjögren’s syndrome. Nat Clin Pract Rheumatol2:252–261.
62.
Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Wolff A -2005-. Sjögren’s syndrome: the diagnostic potential of early oral manifestations preceding hyposalivation/xerostomia. J Oral Pathol Med34:1–6.
63.
Newbrun E -1996-. Current treatment modalities of oral problems of patients with Sjögren’s syndrome: caries prevention. Adv Dent Res10:29–34.
64.
Park K, Case RM, Brown PD -2001-. Identification and regulation of K+ and Cl- channels in human parotid acinar cells. Arch Oral Biol46:801–810.
65.
Paster BJ, Boches SK, Galvin JL, Ericson RE, Lau CN, Levanos VA, et al. -2001-. Bacterial diversity in human subgingival plaque. J Bacteriol183:3770–3783.
66.
Pedersen AM, Bardow A, Nauntofte B -2005-. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjögren’s syndrome. BMC Clin Pathol5:4.
67.
Petersen OH -1992-. Stimulus-secretion coupling: cytoplasmic calcium signals and the control of ion channels in exocrine acinar cells -review-. J Physiol448:1–51.
68.
Rabinov K, Weber AL -1985-. Radiology of the salivary glands. Boston: G.K. Hall Medical Publishers, pp. 231–234.
69.
Radfar L, Shea Y, Fischer SH, Sankar V, Leakan RA, Baum BJ, et al. -2003-. Fungal load and candidiasis in Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod96:283–287.
70.
Ramos-Casals M, Brito-Zerón P -2007-. Emerging biological therapies in primary Sjögren’s syndrome. Rheumatology46:1389–1396.
71.
Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, et al. -1998-. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren’s syndrome. Proc Natl Acad Sci USA95:7538–7543.
72.
Russell SL, Reisine S -1998-. Investigation of xerostomia in patients with rheumatoid arthritis. J Am Dent Assoc129:733–739.
73.
Ryu OH, Atkinson JC, Hoehn GT, Illei GG, Hart TC -2006-. Identification of parotid salivary biomarkers in Sjögren’s syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology45:1077–1086.
74.
Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. -2004-. Etanercept in Sjögren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum50:2240–2245.
75.
Scofield RH, Kurien BT, Reichlin M -1997-. Immunologically restricted, inhibitory anti-Ro in monozygotic twins. Lupus6:395–398.
76.
Scofield RH, Farris AD, Horsfall AC, Harley JB -1999-. Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins -review-. Arthritis Rheum42:199–209.
77.
Scofield RH, Asfa S, Obeso D, Jonsson R, Kurien BT -2005-. Immunization with short peptides from the 60-kD Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjögren’s syndrome. J Immunol15:175:8409–8414.
78.
Shern RJ, Fox PC, Cain JL, Li SH -1990-. A method for measuring the flow of saliva from the minor salivary glands. J Dent Res69:1146–1149.
79.
Ship JA -2002-. Diagnosing, managing, and preventing salivary gland disorders. Oral Dis8:77–89.
80.
Ship JA, Vissink A, Challacombe SJ -2007-. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod103:1–14.
81.
Skibbens RV, Hieter P -1998-. Kinetochores and the checkpoint mechanism that monitors for defects in the chromere segregation machinery. Annu Rev Genet32:307–337.
82.
Steinfeld SD, Delporte C -2002-. Distribution of salivary aquaporin-5 in Sjögren’s syndrome. Lancet359:1777–1778.
83.
Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T -2001-. Infliximab in patients with primary Sjögren’s syndrome: a pilot study. Arthritis Rheum44:2371–2375.
84.
Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, et al. -2006-. Epratuzumab -humanized anti-CD22 antibody- in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther8:129.
85.
Steller M, Chou L, Daniels TE -1988-. Electrical stimulation of salivary flow in patients with Sjögren’s syndrome. J Dent Res67:1334–1337.
86.
Sugata N, Munekata E, Todokoro K -1999- Characterization of a novel kinetochore protein, CENP-H. J Biol Chem274:27343–27346.
87.
Suzuki K, Matsumoto M, Nakashima M, Takada K, Nakanishi T, Okada M, et al. -2005-. Effect of cevimeline on salivary components in patients with Sjögren syndrome. Pharmacology74:100–105.
88.
Szodoray P, Jellestad S, Teague MO, Jonsson R -2003-. Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren’s syndrome. Lab Invest83:357–365.
89.
Szodoray P, Alex P, Brun JG, Centola M, Jonsson R -2004-. Circulating cytokines in primary Sjögren’s syndrome determined by a multiplex cytokine array system. Scand J Immunol59:592–599.
90.
Tabak L, Kuska R -2004-. Saliva transfer can help animals communicate, medicate, or even kill. Evolution has given rise to a variety of salivary mixtures that are being mined for ways to help save human lives. Nat Hist113:32–37.
91.
Tabak L, Mandel ID, Karlan D, Baurmash H -1978-. Alterations in lactoferrin in salivary gland disease. J Dent Res57:43–47.
92.
Takada K, Suzuki K, Okada M, Nakashima M, Ohsuzu F -2006-. Salivary production rates fall with age in subjects having anti-centromere, anti-Ro, and/or anti-La antibodies. Scand J Rheumatol35:23–28.
93.
Tapper-Jones L, Aldred M, Walker DM -1980-. Prevalence and intraoral distribution of Candida albicans in Sjögren’s syndrome. J Clin Pathol33:282–287.
94.
Tengner P, Halse A-K, Haga H-J, Jonsson R, Wahren-Herlenius M -1998-. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren’s syndrome. Arthritis Rheum41:2238–2248.
95.
Thanou-Stavraki A, James JA -2008-. Primary Sjögren’s syndrome: current and prospective therapies. Semin Arthritis Rheum -in press-.
96.
Thomson WM, Chalmers JM, Spencer AJ, Ketabi M -1999-. The occurrence of xerostomia and salivary gland hypofunction in a population-based sample of older South Australians. Spec Care Dentist19:20–23.
97.
Touma Z, Sayad J, Arayssi T -2006-. Successful treatment of Sjögren’s syndrome with rituximab. Scand J Rheumatol35:323–325.
98.
Triantafyllopoulou A, Tapinos N, Moutsopoulos HM -2004-. Evidence for coxsackievirus infection in primary Sjögren’s syndrome. Arthritis Rheum50:2897–2902.
99.
Van Houte J, Gibbons RJ, Banghart SB -1970-. Adherence as a determinant of the presence of Streptococcus salivarius and Streptococcus sanguis on the human tooth surface. Arch Oral Biol15:1025–1034.
100.
Vissink A, Spijkervet FK, Van Nieuw Amerongen A -1996-. Aging and saliva: a review of the literature. Spec Care Dentist16:95–103.
101.
Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. -1993-. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum36:340–347.
102.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. -2002-. European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group -review-. Ann Rheum Dis61:554–558.
103.
Vogelsang P, Jonsson MV, Dalvin ST, Appel S -2006-. Role of dendritic cells in Sjögren’s syndrome. Scand J Immunol64:219–226.
104.
Wallace D -2005-. The new Sjögren’s syndrome handbook. New York: Oxford University Press.
105.
Yarom N, Dayan D, Buchner A, Vered M -2007-. Immunoprofile of focal lymphocytic infiltration in minor salivary glands of healthy individuals. Oral Dis13:274–278.
